Dynatrace Likely to Benefit From Healthy Pipeline, Wedbush Says

MT Newswires Live
02-07

Dynatrace (DT) is well-positioned to benefit from its healthy pipeline driven by Dynatrace Platform Subscription, Wedbush said in a report Thursday after attending a Dynatrace Perform event in Las Vegas.

"We leave the event incrementally more positive on

the DT growth story going into 2025 & beyond that the Street is underestimating," Wedbush analysts, including Daniel Ives, said.

The analysts also said that the AI revolution is picking up, which will provide a stable tailwind for the company going forward.

"We expect DPS adoption to continue to accelerate," they said.

Wedbush kept its outperform rating on the stock with a price target of $67.

Price: 60.72, Change: +0.29, Percent Change: +0.47

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10